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S292 Poster Session I(40%) were females. 23 (53.5%) had high risk cytogenetics and 19
(44%) had non-denovo AML. There was no statistically significant
difference in cytogentic risk (p 5 0.56) or diagnosis of non denovo
AML (p 5 0.18) between the transplant and the non transplant
groups.
Outcomes: CR rate including CR without platelet recovery (CRp)
was 88 % with no induction related deaths. Of the 38 patients who
went into remission 7 (18%) relapsed at a later time point. Median
follow up of the entire cohort was 181days (24 to 987). 20 (47%) pa-
tients were able to proceed to transplant, 6 underwent autologous
SCT, 12 underwent allogeneic SCT and 2 underwent autologous
SCT followed by an allogeneic SCT at relapse. The median time
to first SCT since induction was 115 days (32 - 195). Median OS
was 11.3 months. Median OS of the patients who underwent SCT
is *not reached vs 5.1 months for the non transplant group (p 5
0.0055). Median PFS of patients who underwent SCT was *not
reached vs 5.9 months for the non transplant group, (p 5 0.0229).
Conclusions: In this high risk AML population, HiDAC/MITO in-
duction was well tolerated and demonstrated an excellent CR/CRp
rate of 88% with no induction deaths. Substantial number (47%)
of patients proceeded to SCT and had a significantly better outcome
(both OS and PFS).237
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Introduction: AML patients over age 65 years have a poor outcome
with a median survival of 2 months and a 2-year survival rate of 6%
(Menzin et al Arch Intern Med. 2002). Allo-SCT is curative in AML
but is frequently not offered to older patients because of the concern
of high mortality associated with this procedure.
Methods: Retrospective analysis was performed on all patients with
AML over age 65 years who underwent an allo-SCT at UMass Me-
morial Medical Center since 2009. The study was approved by
UMass Memorial Medical Center IRB.
Results: 9 patients were identified from the database. There were 6
men and 3 women. Median age at SCT was 69 years range (65-78). 4
patients were$70 years of age. Disease status at SCT was complete
remission (CR) in 4 (44%) and persistent disease in 5 (56%) patients.
Median number of chemotherapy cycles prior to SCT was 3 range
(1-14). 1 patient had 2 prior autologous SCT. 5 (55%) patients
had poor prognostic cytogenetics (including Flt-3 ITD) and 6
(67%) patients had preceding MDS. Median time from diagnosis
to SCT was 197 days range (105-2240). Stem cell source was single
cord blood (CB) unit in 3 and unrelated donor in 6 patients. Prepar-
ative regimen was myeloablative in 4 (Thiotepa10mg/kg/Flu/Mel
140mg/m2/rabbitATG in 3 CB-SCT; Flu/Bu3.2mg/kg x 3/ATG
in 1) and reduced intensity in 5 patients (Flu/Bu3.2mg/kg x 2/
ATG). Graft versus host disease (gvhd) prophylaxis was tacroli-
mus/mycophenolate mofetil (MMF) in 6 and sirolimus/MMF in 3
subjects.Median number of stem cell infusedwas 4.99 x106 /kg range
(1.7 x105- 6.14 x106). All 9 patients engrafted with full donor chime-
rism and were in CR post SCT.Median time for neutrophil engraft-
ment was 18 days range (13-41) and platelet engraftment was 13 days
range (11-73). Grade II-IV acute gvhd developed in 2 patients. Day
100 survival was 8/9 (89%). The Kaplan-Meier Product-Limit esti-
mates show that the long-term survival probability is 0.78 and is sta-
ble at that level after 6 months. Four patients have survival times
longer than one year with two patients surviving beyond two years.
No patient relapsed post SCT. All surviving patients have Karnofsky
performance score $80. 2 patients are off all immunosuppressant
therapy.
Conclusion: Allogeneic SCT is safe and effective treatment modal-
ity for elderly AML patients. This treatment modality needs to be
validated in prospective clinical trials.238
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Background: Pre-transplant consolidation therapy for patients with
AML in the first complete remission (CR) decreases leukemia recur-
rence and improves survival.
Patients and Methods: 29 AML patients (15 females and 14 males)
with a median age of 33 years (range 18-63) enrolled from Feb. 2010
to Oct. 2011 were randomly allocated into two groups. 14 patients in
the first group (A) received 7+3 chemotherapy regimen (cytarabine
100mg/m2/day for 7 days+ idarubicin 12mg/m2/day for 3 days) prior
to hematopoietic stem cell transplantation (HSCT) and 15 patients
in the second group (B) received 7+3 regimen followed by 5+2 (cytar-
abine 100mg/m2/day for 5 days+ idarubicin 12mg/m2 for 2 days) be-
fore HSCT. All Patients were in complete remission before
transplantation. Peripheral blood stem cells were the preferred
source for transplantation.
Results: The median time from diagnosis to transplant was 70.5
days in the B and 171 in the A group. The median time to absolute
neutrophil count $ 0.5*10^9/L was +13 days in the B and + 14
in the A group (p 5 0.18). The median time to platelet count $
20000 was +15 days in the B and +16 in the A group (p5 0.32). Me-
dian follow-up time was 128 days. Acute GVHD occurred in 7
(46.7%) patients in the B and in 11 (78.6%) patients in the A group.
Themost common grade of acute GVHDwas grade II for 3 (42.9%)
and 8 (72.7%) patients in the B and A groups, respectively. At this
time, 24 patients (82.3%) are still alive (13 in the B & 11 in the A
group). The causes of death were GVHD in 3 patients (1 in the B
and 2 in the A group), relapse (1 patient in the B group) and CMV
infection (1 patient in the A group). 4-month overall survival was
92.3% (SE: 7.4%) and 80% (SE: 12.6%) in the B and A groups, re-
spectively (p5 0.4). 4-monthLeukemia-free survival was 82.1% (SE:
11.7%) in the B and 80% (SE: 12.6%) in the A group (p 5 0.64).
The cumulative incidence of acute GVHD on +12 days was 20%
(95% C.I.: 5%-43%) in the B and 64% (95% C.I.: 32%-84%) in the
A group that was statistically significant (p 5 0.032).
Conclusion: Preliminary results show that omitting consolidation
therapy prior to hematopoietic stem cell transplantation has no ad-
verse impact on survival outcome in short-term follow-up of pa-
tients, but reduces the cumulative incidence of acute GVHD after
transplantation. More cases and longer duration of follow-ups are
needed to achieve significant results.239
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SOCIATED WITH CD25 EXPRESSION IN ACUTE MYELOID LEUKEMIA
(AML): ARETROSPECTIVE SINGLE CENTER ANALYSIS
Cerny, J.1, Ramanathan, M.1, Yu, H.1, Raffel, G.D.2, Walsh, W.V.1,
Petrillo-Deluca, L.J.1, Tarrasky, N.1, O’Rourke, E.1, Bednarik, J.1,
Hao, S.2, Hutchinson, L.2, Woda, B.2, Barton, B.3, Rosmarin, A.G.1,
Nath, R.1 1University of Massachusetts Medical School, Worcester, MA;
2University of Massachusetts Medical School, Worcester, MA; 3University
of Massachusetts Medical School, Worcester, MA
We have recently identified that expression of CD25 on leukemic
blasts as a novel prognostic marker associated with high relapse rate
and short relapse free survival (RFS). CD25+ was a more robust pre-
dictor of AML relapse (multivariate Cox regression analysis HR 6.54
[1.34-9.15], p 5 0.01; FLT3-ITDmut: HR 4.72 [2.04-10.92], p 5
0.03). CD25+ leukemic cells resembled behavior of leukemic stem
cells (LSCs) as described by Saito et al (Sci Transl Med 2010). We
report the effect of stem cell transplantation (SCT) on outcome of
pts with CD25+ AML.
We retrospectively examined the impact of SCT in 46 AML pa-
tients eligible for induction therapy (excluding APL) in whom
CD25 was assessed.
Median age was 61 years (range, 22-84); 19 were (41%) female.
CD25 was detected in 17 pts (37%). No difference was seen in the
following factors: gender, age, cytogenetics, or presence of
